HC Wainwright & Co. Initiates Coverage On Reviva Pharmaceuticals with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy rating and announces Price Target of $10.
48 Biggest Movers From Yesterday
Gainers
Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT performance drink in Walmart stores across Florida metropolitan areas.
30 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.
RVPH: FDA Allows IND; Imminent Start to Phase III
By John Vandermosten, CFA
NASDAQ:RVPH
READ THE FULL RVPH RESEARCH REPORT
21 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
OneSmart International Education Group Limited (NYSE: ONE) rose 39.1% to $0.2701 in pre-market trading. OneSmart International Education Group received notification from NYSE regarding delayed Form 20-F filing.
FDA Gives Green Signal To Reviva Pharma’s Late-Stage Schizophrenia Trial
The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it m